Chardan Capital reissued a "buy" rating on shares of Healthequity in a report on Monday, February 13th. Zacks Investment Research upgraded shares of Healthequity from a "sell" rating to a "hold" rating in a report on Saturday, March 4th. The rating was initiated by Bernstein with "Outperform" on Monday, August 22.
Shares of Healthequity Inc (HQY) traded up 0.73% during midday trading on Monday, reaching $48.41. Analysts, on average, seem bearish as they suggest HQY is worth $-0.48 less, giving a target price of $52.2 a share.
On Thursday, March 16th, Stephen Neeleman sold 40,169 shares of Healthequity stock. They set an "overweight" rating and a $50.00 price objective on the stock. The rating was upgraded by Jefferies on Tuesday, December 13 to "Buy". Healthequity now has an average rating of "Buy" and a consensus price target of $46.00. On Wednesday, September 7 the stock rating was maintained by Robert W. Baird with "Neutral". The stock has a market capitalization of $2.89 billion, a price-to-earnings ratio of 110.02 and a beta of 1.94.
HealthEquity, Inc. mean recommendation is 1.80 (1=Buy, 5=sell). The stock has a 50-day moving average of $45.74 and a 200-day moving average of $44.01. The stock of Healthequity Inc (NASDAQ:HQY) earned "Buy" rating by Chardan Capital Markets on Tuesday, December 13. As of the last earnings report the EPS was $0.44 and is estimated to be $0.53 for the current year with 59,628,000 shares now outstanding. Healthequity had a net margin of 15.19% and a return on equity of 11.08%. The company had revenue of $55.40 million during the quarter, compared to the consensus estimate of $54.77 million. During the same quarter a year ago, the firm posted $0.07 earnings per share. The business's quarterly revenue was up 30.4% compared to the same quarter previous year. On average, equities analysts predict that Healthequity will post $0.53 EPS for the current fiscal year.
WARNING: This piece was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another website, it was stolen and republished in violation of US and worldwide trademark and copyright law. The correct version of this article can be viewed at https://sportsperspectives.com/2017/06/08/insider-selling-healthequity-inc-hqy-insider-sells-1934400-00-in-stock.html. Goldman Sachs Group Inc now owns 65,898 shares valued at $2,797,000. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
HealthEquity, Inc. (NASDAQ:HQY)'s latest quote $52.68 $1.7 8.64% will find technical support in $49.84 a share and a breakdown below this region would be a significantly bearish signal for HealthEquity, Inc. traders. After this sale, 1,103,285 common shares of HQY are directly owned by the insider, with total stake valued at $58,121,054. The disclosure for this sale can be found here. Insiders have sold a total of 310,950 shares of company stock valued at $14,127,986 over the last 90 days.
A number of research analysts have weighed in on the stock. Finally, State of Alaska Department of Revenue boosted its stake in shares of Healthequity by 4.3% in the first quarter. Neuburgh Advisers LLC now owns 31,968 shares of the company's stock valued at $1,357,000 after buying an additional 112 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Healthequity during the fourth quarter worth about $848,000.
Stock: Shares were up 1.8% at 69.36 in midday trading on the stock market today, after earlier entering profit-taking sell territory, which starts at 70.02. On a one to five ratings scale where 1.0 indicates a Strong Buy, 2.0 indicates a Buy, 3.0 a Hold, 4.0 a Sell and 5.0 a Stong Sell. Finally, Bank of New York Mellon Corp increased its stake in Healthequity by 47.9% in the first quarter. Allegis Investment Advisors LLC now owns 10,237 shares of the company's stock valued at $435,000 after buying an additional 237 shares in the last quarter.